Company news

Personalis, Inc. news in 2026

Personalis, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Personalis Reports Third Quarter Results

November 4, 2026

Personalis NeXT Personal® Data Showcasing Ultrasensitive MRD to be Presented at ESMO 2026

October 21, 2026

Personalis Brings Resistance Mutation Tracking to NeXT Personal® MRD Test

October 20, 2026

Personalis Reports Second Quarter Results and Recent Highlights

August 4, 2026

Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform

July 20, 2026

Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain

July 14, 2026

Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits

June 9, 2026

Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026

June 2, 2026

Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium

May 26, 2026

Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring

May 20, 2026

Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors

May 13, 2026

Personalis Reports First Quarter Results and Recent Highlights

May 7, 2026

Personalis to Announce First Quarter 2026 Financial Results

April 23, 2026

Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026

April 21, 2026

Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026

April 13, 2026

Personalis to Participate in the 25th Annual Needham Virtual Conference

April 1, 2026

Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption

March 16, 2026

Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal®

March 11, 2026

Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

February 26, 2026

Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference

February 17, 2026

Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results

February 12, 2026

Personalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer Surveillance

February 10, 2026

Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors

February 1, 2026

Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

January 28, 2026

Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™

January 11, 2026

Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights

January 7, 2026

Calls in 2026

Decks in 2026